Printer Friendly

NOCOPI ANNOUNCES EUROPEAN AGREEMENT

 NOCOPI ANNOUNCES EUROPEAN AGREEMENT
 WAYNE, Pa., April 24 /PRNewswire/ -- Nocopi International, Inc.


(OTC Bulletin Board: NOOP) and Applied Holographics Plc. of London, today announced that they had entered into a marketing agreement for Nocopi's reactive imaging technology for the United Kingdom and Ireland.
 The announcement was made by Dr. David Tidmarsh, managing director and chief executive officer of Applied Holographics, and Norman A. Gardner, president and chief executive officer of Nocopi.
 Applied Holographics is Europe's leading hologram company and is a world innovator in the research and development of commercial holography. The company supplies holograms to major security printers throughout the United Kingdom and Europe. Its best known security hologram, that of William Shakespeare, currently is in use by the Association for Payment Clearing Services which represents the major clearing banks in the United Kingdom.
 Glaxo Laboratories Ltd. was the first pharmaceutical company in the United Kingdom to use holograms which were supplied by Applied Holographics to protect its leading medicine, Zantac, against drug counterfeits.
 "Counterfeiting is one of the world's fastest-growing crimes," said Tidmarsh.
 "We view the addition of the Nocopi product line to our core hologram business as an immense advantage in dealing with this growing problem. The Nocopi technology is an ideal complement to our hologram product."
 Nocopi International, Inc., based in Wayne, is a publicly traded U.S. corporation which owns a patented technology to prevent photocopying and faxing of confidential information as well as a system to verify the originality of documents and products.
 /delval/
 -0- 4/24/92
 /CONTACT: Norman A. Gardner, president and chief executive officer of Nocopi International, 800-662-6741, or 215-687-2000/
 (NOOP) CO: Nocopi International, Inc.; Applied Holographics Plc. ST: Pennsylvania IN: SU: CON


MP-MK -- PH006 -- 2309 04/24/92 09:23 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 24, 1992
Words:291
Previous Article:POTENTIAL NEW CANCER THERAPEUTIC DEVELOPED BY IMMUNOMEDICS AND NATIONAL CANCER INSTITUTE TEAM; RESULTS PRESENTED AT CANCER MEETING
Next Article:DONNELLY CORPORATION ANNOUNCES DIVIDEND


Related Articles
NOCOPI COMPLETES $3 MILLION EUROPEAN OFFERING
GLOBE ACQUIRES EXCLUSIVE RIGHTS TO NOCOPI TECHNOLOGY
NOCOPI AND SCIENTIFIC GAMES SIGN AGREEMENT
NOCOPI ANNOUNCES MAJOR AGREEMENT
NOCOPI SIGNS EXCLUSIVE AGREEMENT FOR CHINA
AVERY DENNISON SIGNS EXCLUSIVE AGREEMENT WITH NOCOPI TO MARKET COUNTERFEIT-DETECTION TECHNOLOGY
NOCOPI COMPLETES EUROPEAN OFFERING, SIGNS EXCLUSIVE U.S. LICENSEE
Nocopi Wins European Litigation.
NOCOPI WINS EUROPEAN LITIGATION.
NOCOPI LAUNCHES EUROPEAN MARKETING.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters